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ABSTRACT 
 
The congenital myopathies (CMs) are a group of early-onset, non-dystrophic neuromuscular 
conditions with characteristic muscle biopsy findings, variable severity and a stable or slowly 
progressive course. Muscle weakness pronounced in axial and proximal muscle groups is 
common, whereas the degree of extraocular muscle weakness, cardiorespiratory and distal 
muscle involvement may implicate specific genes. Based on the predominant muscle biopsy 
finding, Central Core Disease (CCD), Multi-minicore Disease (MmD), Centronuclear 
Myopathy (CNM) and Nemaline Myopathy (NM) were the main CMs to be originally 
reported and still represent the major diagnostic categories. Mutations in more than 20 genes 
have been identified to date, encoding proteins implicated in skeletal muscle calcium 
homeostasis, excitation-contraction coupling (ECC), thin/thick filament assembly and 
interactions, and other mechanisms. Mutations in the skeletal muscle ryanodine receptor 
(RYR1) gene are the most frequent genetic cause, and CCD and MmD (the “core 
myopathies”) are the most common subgroups. Widespread introduction of next generation 
sequencing (NGS) has vastly improved mutation detection in large genes such as RYR1, 
nebulin (NEB) and titin (TTN), and identified novel genetic backgrounds. There is an 
increasing recognition that the originally described entities represent a partially skewed 
selection of a much wider phenotypical spectrum, as many patients may show only subtle, 
non-specific or multiple histopathological features, evading easy categorization. Most of the 
principal mechanisms have been largely resolved, but the etiology of the pathognomic 
histopathological features and secondary effects on muscle growth and atrophy pathways 
remain only poorly understood.  Whilst so far management has been mainly supportive, 
therapy development is reaching the clinical trial stage in some conditions. 
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INTRODUCTION 
 
The congenital myopathies (CMs) are a genetically heterogeneous group of early-onset 
muscle conditions characterized by variable degrees of muscle weakness and characteristic 
structural abnormalities on muscle biopsy. They are almost invariably disorders of disturbed 
ECC, the process whereby an electrical neuronal impulse is translated into muscle contraction 
through controlled Ca
++
 release leading to sarcomeric protein activation, or of proteins 
primarily involved in sarcomeric filament assembly and interaction.  Nevertheless, recent 
findings suggest other less common pathogenic mechanisms. The concept of the CMs was 
established in the 1950s and 1960s, when the application of histochemical and ultrastructural 
techniques to diseased muscle identified histopathological features considered to be 
pathognomonic at the time. Recognition of these features – central cores, multi-minicores, 
central nuclei, nemaline rods – resulted in the designation of novel disease entities – Central 
Core Disease (CCD) 
1
, Multi-minicore Disease (MmD) 
2
, Centronuclear Myopathy (CNM) 
3
 
and Nemaline Myopathy (NM) 
4
 – that still represent the major diagnostic categories.  
Considerable progress has been made concerning the understanding of the phenotypical 
spectrum, diagnosis and management of the CMs. In addition to primary myopathic features, 
non-neuromuscular manifestations are observed in several forms, pointing to a role of the 
defective proteins in non-skeletal muscle tissues 
5
. Muscle imaging, in particular muscle 
magnetic resonance imaging (MRI), has emerged as a powerful tool for deep phenotyping 
6
. 
Presentations late in adulthood have now been recognized 
7,8
, and due to improved standards 
of care, even patients with severe early-onset forms increasingly transition from paediatric to 
adult neurology services. 
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Since the identification of dominant mutations in the skeletal muscle ryanodine receptor 
(RYR1) gene as the cause of Malignant Hyperthermia (MH) in 1991 and CCD in 1993 
9,10
, 
mutations in more than 20 genes have been identified. Introduction of next generation 
sequencing (NGS) techniques into routine clinical diagnosis 
11
 has resulted in an improved 
detection rate of mutations in genes such as RYR1, nebulin (NEB) or titin (TTN), due to their 
sheer size previously only studied with Sanger sequencing in few patients. These novel 
techniques have led to the recognition that different mutations in the same gene may give rise 
to variable histopathological phenotypes, whilst mutations in different genes may cause the 
same histopathological feature, often due to functional association of the defective proteins. 
Moreover, it has also become increasingly clear that in many CMs, non-specific or a 
combination of pathological abnormalities rather than a “pure” muscle pathology picture may 
be found. A classification based on predominant histopathological and associated clinical 
features is still practically useful; however, it is also helpful to consider these conditions 
according to the main underlying disease mechanisms.  
In the present review, we will summarize genetic, clinical and pathological features of the 
major CMs. Common pathogenic mechanisms, diagnostic and current management 
approaches, and principles of therapy development will be outlined.  
 
CLASSIFICATION AND EPIDEMIOLOGY 
 
Data concerning the precise epidemiology of the CMs are limited, and mostly focused on the 
originally described major pathological variants, CCD, MmD, CNM and NM; the key 
characteristics of these entities are detailed below and illustrated in Figure 1.  
CCD, initially described in the 1950s 
1
, and MmD 
2
 (also often referred to as the “core 
myopathies” 12) derive their name from the histochemical appearance of focally reduced 
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oxidative enzyme activity, corresponding to myofibrillar changes on ultrastructural 
examination. Centrally located, well-demarcated cores running along a significant extent of 
the fibre axis on longitudinal sections are characteristic of CCD, whilst multiple cores of less 
well-defined appearance and of longitudinally more limited extent define MmD. 
The hallmark of CNM is fibres with centralized nuclei, which vary in number and in terms of 
associated features between muscles and genetic backgrounds. NM (for review, 
13
) is 
characterized by the presence of numerous nemaline rods that stain red on the Gomori 
trichrome and are confirmed on EM. 
The overall prevalence of these CM variants has been estimated at 1 in 26000 
14
. While 
originally NM was considered the most frequent form, emerging data suggest that CMs with 
cores (CCD, MmD) are the most common subgroup. Marked genetic heterogeneity is now 
acknowledged and detailed in the sections on the major diagnostic categories below. In 
essence, recent data indicate that RYR1 is the gene most frequently involved in the CMs, in 
particular CCD and MmD. Recessive NEB mutations and (de novo) dominant mutations in 
ACTA1 encoding skeletal muscle alpha-actin are the most common known causes of NM, 
whereas X-linked recessive mutations in MTM1 encoding myotubularin are believed to be the 
most common cause of CNM. Mutations in TTN are increasingly being recognized and may 
be implicated in a substantial proportion of currently unresolved CMs, as well as other 
neuromuscular disorders, including muscular dystrophies 
15
. The genes implicated in the CMs 
are listed in Table 1 and the key clinico-pathological features associated with the most 
common genetic backgrounds are summarized in Table 2. Characteristic histopathological 
features are illustrated in Figure 1.   
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CLINICO-PATHOLOGICAL AND GENETIC FEATURES 
 
Congenital myopathies with cores – CCD, MmD and MH 
 
In view of the pathological and genetic overlap, CCD, MmD (also referred to as the “core 
myopathies”) and MH are discussed here in a single section.  
CCD is most closely linked to dominant RYR1 mutations, whereas MmD is genetically more 
heterogeneous, mainly due to recessive mutations in RYR1 
16-18
, SEPN1 encoding 
selenoprotein N 
19
 and, less frequently, MYH7 
20
. The histopathological appearance of MmD 
has also been described in some patients with recessive mutations in MEGF10 encoding 
multiple epidermal growth factor 10 
21-24
. (Mini)cores on muscle biopsy may also be 
prominent in TTN-related myopathies 
25
, often in conjunction with other myopathic and 
dystrophic features, and may also occur in other neuromuscular disorders. 
Clinically, CCD due to dominant RYR1 mutations (for review, 
12
) is usually a relatively mild 
condition, although early severe presentations, often associated with de novo inheritance, are 
on record 
26
. Extraocular muscles are usually spared and facial, bulbar and respiratory 
involvement is typically mild. Congenital dislocation of the hips (CDH) and scoliosis are 
common. Most patients achieve independent ambulation and have a static or only slowly 
progressive course. Clinical features of predominantly recessively inherited MmD (for review 
12
), are more variable. SEPN1-related myopathies 
19,27
 are characterized by marked weakness, 
early spinal rigidity, scoliosis and respiratory impairment. Recessively inherited RYR1-related 
core myopathies show a distribution of weakness and wasting similar to the SEPN1-related form 
but have additional extraocular muscle involvement and, with few exceptions, lack the severe 
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respiratory impairment 
17,18
. Variable combinations of scoliosis, spinal rigidity, multiple, mainly 
distal contractures and an associated cardiomyopathy may occur in TTN- and MYH7-related 
forms 
20,25
. MEGF10-related myopathies are associated with a very wide spectrum, ranging from 
a severe early-onset myopathy with areflexia, respiratory distress and dysphagia (termed 
EMARDD) 
21,23,24
 to adult-onset cases with minicores on muscle biopsy
22
. Muscle MRI may 
help to differentiate genetically distinct core myopathies 
28,29
.    
Dominant RYR1-related CCD is allelic to the Malignant Hyperthermia Susceptibility (MHS) 
trait, a pharmacogenetic predisposition to MH, a severe adverse reactions to volatile anaesthetics 
and muscle relaxants (for review, 
30
), with some CCD-associated RYR1 mutations also carrying 
an increased MHS risk. The association with recessive RYR1-related MmD is less well-
established; however, MmD cases due to compound heterozygosity for dominant MHS RYR1 
mutations are on record 
18,31,32
.  
RYR1-related King-Denborough syndrome (KDS) is an MHS-associated myopathy 
characterized by dysmorphic facial features, short stature, spinal rigidity, scoliosis and variable 
histopathological features 
33
. Another recently recognized myopathy with similar clinico-
pathological features is Native American myopathy (NAM), originally described in the Lumbee 
population of North Dakota and due to homozygosity for a founder mutation (p.W284S) in 
STAC3  
34
.  
MHS-associated RYR1 mutations have now also been identified as a common cause of 
exertional myalgia and rhabomyolysis (ERM) in otherwise healthy individuals with variable 
muscle biopsy findings 
35
. Of note, exertional myalgia may be prominent in CCD 
36
, where mild 
to moderate CK elevations (up to 1000 IU/l), unusual in the context of other CMs, are also not 
uncommon. MHS-associated RYR1 mutations may also give rise to a late-onset axial myopathy 
in previously healthy (or even particularly athletic) individuals 
37,38
.  
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Centronuclear Myopathy (CNM) 
 
CNM (for review, 
39
 ) is associated with X-linked recessive mutations in MTM1 encoding 
myotubularin (X-linked myotubular myopathy, XLMTM) 
40
, autosomal-dominant mutations in 
DNM2 encoding dynamin 2 
41
 and BIN1 encoding amphiphysin 2 
42
, and autosomal-recessive 
mutations in RYR1 
43
, BIN1 
44
, and TTN 
45
. Recessive mutations in SPEG have been identified in 
a small number of families 
46
 and dominant mutations in CCDC78 
47
 in one isolated pedigree. 
Heterozygous missense variants in MTMR14 (or hJUMPY) identified in 2 patients with CNM 
may represent a genetic modifier of other genetic backgrounds 
48
. 
In MTM1-related cases, the central nuclei are usually spaced down the long fibre axis, 
whereas in DNM2-related cases they may form chains; in the rare BIN1-related cases, clusters 
of central nuclei may occur. A typical feature of MTM1-related cases is central areas of 
enhanced oxidative enzyme activity and a pale peripheral halo. This finding and central 
nuclei are features shared with congenital myotonic dystrophy. Strictly centralized nuclei are 
more common than multiple internalized nuclei in the MTM1-, DNM2- and BIN1-related 
forms 
40,41,44
, whereas the opposite applies to RYR1-and TTN-related cases 
43
. A radial 
distribution of sarcoplasmic strands with staining for NADH-TR and PAS is often seen in 
DNM2-related CNM 
41. “Necklace” fibres are often seen in milder MTM1-mutated cases or 
female carriers 
49
, and, occasionally, DNM2-related cases 
50
. In most forms, ultrastructural 
triad abnormalities are observed 
51
.  
Clinically, extraocular muscle involvement is the most consistent feature in all forms (for 
review 
52
) except the TTN-, SPEG- and CCDC78-related form. The most severe form, 
XLMTM, typically presents in affected males with profound hypotonia, weakness and 
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contractures at birth, and associated bulbar and respiratory involvement almost always 
necessitating ventilation for survival. While the provision of constant respiratory support 
does improve life-expectancy in XLMTM there are recognized complications in some long-
term survivors 
53
, probably related to the ubiquitous role of the defective protein. Dominantly 
inherited CNM associated with mutations in DNM2 is frequently a relatively mild condition 
41,54
, although more severe de novo cases are on record 
55,56
. Additional characteristic features 
may include distal weakness, calf muscle hypertrophy, exertional myalgia/fatigue, peripheral 
or central nervous system involvement, and multisystem features such as neutropenia or 
cataracts. The peripheral axonal neuropathy CMTDIB is an allelic condition 
57
. Recessive 
and, less frequently, dominantly inherited and milder, BIN1-related CNM have been reported 
in few families 
42,44,58
. Recessively inherited CNM due to RYR1 mutations 
43
 shows 
considerable clinical overlap with other forms of recessively inherited RYR1-related 
myopathies (see above). Mutations in TTN are often associated with dysmorphic facial 
features, scoliosis, spinal rigidity and contractures 
45
, showing some overlap with the Emery-
Dreifuss muscular dystrophy (EDMD) and the KDS spectrum. Cardiac involvement has only 
been reported in the TTN- and SPEG-related forms.  
 
Nemaline Myopathy (NM) 
 
NM has been associated with mutations in more than 10 genes to date, most commonly 
recessive mutations in the nebulin (NEB) gene 
59,60
, and (de novo) dominant mutations in the 
slow skeletal muscle α-actin (ACTA1) gene 61. Dominant mutations in the alpha-tropomyosin 
(TPM3) 
62
, the beta-tropomyosin (TPM2) 
63
 and the KBTBD13 
64
 genes, as well as recessive 
mutations in ACTA1 
65
, in TPM3 
66
, TPM2 
67
 the slow troponin T (TNNT1) 
68
, cofilin-2 
(CFL2) 
69
, Kelch-repeat and BTB (POZ) domain containing 13 (KBTBD 13) 
64
 , KLHL40 
70
 , 
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KLHL41 
71
, leiomodin-3 (LMOD3) 
72
 , myopalladin (MYPN) 
73,74
 and myosin XVIIIB 
(MYOB18) 
75
are less common or even limited to single families.  
The number and distribution of nemaline rods varies between muscles and patients. Rods are 
believed to be derived from Z-lines, and may show continuity with Z-lines; they are mainly 
cytoplasmic but may also be nuclear, in particular in ACTA1-related NM 
76
 where there may 
be additional actin accumulation and compensatory expression of cardiac actin.  Nemaline 
rods are usually seen in both fibre types except in patients with TPM3 mutations, where they 
are limited to type 1 fibres. Numerous small rectangular rods in fibres with very few 
myofibrils are a feature of KLHL40-related NM 
70
. 
Clinically, NM is highly variable and conventionally classified by age of onset and severity: 
Profoundly severe, often lethal cases within the fetal akinesia spectrum have been reported in 
association with recessive mutations in KLHL40 
70
, KLHL41 
71
, LMOD3 
72
 and MYO18B
75
 
whereas the “typical” congenital form of NM characterized by infantile onset, hypotonia and 
often disproportionate bulbar involvement is most commonly due to recessive NEB mutations 
77
. Dominant (frequently de novo) ACTA1 mutations are often associated with severe 
congenital presentations, but milder cases have been reported 
65,78-80
. KBTBD13-gene related 
NM is an unusual form characterized by progressive proximal and neck weakness, gait 
abnormalities, poor exercise tolerance and a peculiar slowness of movements 
81
. Extraocular 
muscle involvement is only seen in a proportion of cases with KLHL40, KLHL41 and 
LMOD3 mutations. An associated cardiomyopathy may be seen in MYPN- and MYO18B-
associated NM 
74,75
. Many forms of NM may show marked distal involvement, and many of 
the causative genes have also been implicated in distinct distal arthrogryposis (DA) 
syndromes (for example, 
82
). Muscle MRI may help to distinguish different genetic forms of 
NM 
83
.  
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Other congenital myopathies 
 
Recent years have seen an expansion of the phenotypical spectrum of already known CM-
associated genes, as well as the description of novel conditions that share some of the clinical 
and muscle biopsy findings with the better characterized entities without reaching a 
comparable level of histopathological “purity”. These CMs with non-specific, multiple 
(structural) and unusual/other features are summarized in the following paragraph. 
CMs with non-specific features. Marked type 1 predominance or uniformity is common in 
all CMs and may be the sole presenting feature 
84
. Marked type 1 predominance and atrophy 
has also been reported in one consanguineous family with clinical features of a congenital 
myopathy and recessive mutations in HACD1 encoding 3-hydroxyacyl-CoA dehydratase 1
85
; 
although recessive mutations in the corresponding canine gene PTPLA cause a form of CNM 
in dogs 
86,87
, increased central nuclei were not a feature in HACD1-mutated humans. 
Congenital fibre type disproportion (CFTD), the marked smallness of type 1 fibres 
compared to type 2 fibres, is another common feature that has been reported in association 
with mutations in TPM3 
88,89
, RYR1 
90
, ACTA1 
91
, SEPN1 
92
 and MYH7 
93
, with or without 
additional structural abnormalities.  
CMs with multiple (structural) abnormalities, already recognized in the pre-molecular era 
94
, have now been largely genetically resolved and are often attributed to already previously 
identified genetic backgrounds: The common occurrence of cores and rods (“core-rod 
myopathy”) has been attributed to mutations in RYR1, ACTA1 and NEB, whereas the 
combination of cores and central nuclei is seen with RYR1, TTN, CCDC78, DNM2 and SPEG 
12 
 
mutations. There is also a rapidly increasing number of novel entities that do not readily fit 
into the conventional classification based on a single predominant histopathological 
abnormality:  CACNA1S-related myopathy 
95
 is characterized by marked neonatal hypotonia, 
generalized weakness pronounced axially and variable extraocular, bulbar and respiratory 
involvement. CACNA1S-related myopathy is due to recessive and dominant mutations in the 
gene encoding the pore-forming subunit of DHPR in skeletal muscle (Cav1.1), previously 
associated with dominantly inherited forms of periodic paralysis (and, rarely, MHS phenotypes) 
96,97
. Characteristic histopathological features include SR dilatation, increased internal nuclei 
and myofibrillar disorganization resembling minicores. Recessively inherited, PYROXD1-
related CM 
98
 is an early-onset myopathy of moderate severity characterized by slowly 
progressive generalized weakness, facial and bulbar involvement, and increased internalized 
nuclei and myofibrillar disorganization on muscle biopsy. Hereditary myosin myopathies 
(“myosinopathies”) (for review, 99) comprise distinct distal arthrogryposis (DA) syndromes 
due to dominant mutations in MYH3 and MYH8 encoding two developmental myosin heavy 
chain (MyHC) isoforms, as well as CMs of variable onset and severity due to dominant and 
recessive mutations in MYH2 and MYH7, the latter also implicated in Laing distal myopathy 
and myosin storage myopathy (MSM). In addition to the variable presence of cores on 
muscle biopsy, (recessive) MYH2-related myopathies 
100-102
 show marked reduction (or 
absence) of type 2A fibres 
99,103, whereas accumulation of slow myosin (“hyaline bodies”) 
may be seen in some MYH7-related cases. Both MYH7- and MYH2-related myopathies may 
also show increased connective tissue, internal nuclei, rimmed vacuoles, ring and lobulated 
fibres 
20,93,99,103
. In the context of overlapping histopathological features, the presence of 
extraocular muscle involvement may cause diagnostic confusion with recessive RYR1-related 
MmD. Two other conditions combining ocular involvement, contractures within the DA 
spectrum and features of a CM are recessively inherited ECEL1-related CM 
104-108
 and 
13 
 
dominantly inherited PIEZO2-related CM 
109
 (also classified as DA5), both associated with 
cores and increased internal nuclei on muscle biopsy. A recessive SCN4A-related CM due to 
homozygous or compound heterozygous mutations in SCN4A 
110
, encoding the α-subunit of 
the skeletal muscle voltage-gated sodium channel (Nav1.4) and previously associated with 
dominantly inherited myotonia and periodic paralysis has been recently described associated 
with a wide spectrum, from severe in utero (often early lethal) presentations to neonatal-onset 
conditions of variable severity. The phenotype is mainly characterised by hypotonia, facial 
and neck weakness, respiratory and swallowing difficulties and early-onset spinal deformities 
but interestingly, no clinical or electrophysiological evidence of myotonia. Mutations in the 
same gene have also been associated with a presentation featuring severe neonatal 
laryngospasm 
111
. Histopathological features are characterized by a combination of increased 
fibre size variability and variable increases in fatty tissue, but do usually lack more distinct 
structural abnormalities
110
. Many of the genetic backgrounds implicated in the CMs – in 
particular RYR1, TTN and DNM2 – may show marked increases in fat and connective tissue, 
features mimicking a congenital muscular dystrophy 
112,113
.   
CMs with unusual or other features: Some of the genes associated with NM - TPM2, 
TPM3, ACTA1, NEB and MYPN – have also been implicated in rare myopathies with unusual 
histopathological features, Cap myopathy and Zebra body myopathy 
73,114-116
. STIM1- and 
ORAI1-related CMs (for review, 
117
) due to dominant gain-of-function mutations result in either 
tubular aggregate myopathy (TAM), a slowly progressive myopathy with variable extraocular 
muscle involvement, exertional myalgia and variable calf hypertrophy, or York platelet and 
Stormorken syndromes, related disorders with a CM, pupillary and platelet abnormalities, and 
variable multisystem involvement that form a clinical continuum. Recessive inheritance of loss-
of-function mutations in ORAI1 and STIM1 lead to variable combinations of a severe combined 
immunodeficiency, ectodermal dysplasia and a CM, a combination reported already in the 
14 
 
pre-molecular era in association with minicores on muscle biopsy 
118
. The “triadin knockout 
syndrome” due to compound heterozygosity for TRDN (null) mutations is a recessive cardiac 
arrhythmia syndrome with variable clinical and histopathological features of a CM, the latter 
characterized by focal dilation and degeneration of the lateral SR cisternae 
119,120
; the highly 
variable penetrance of the myopathy associated with this entity remains however currently 
unaccounted for. Mutations in TRIM32, TRIM54 and TRIM63 (encoding an ubiquitin E3 
ligase and muscle-specific RING finger proteins MuRF3 and 1, respectively) have been 
associated with LGMD2H, sarcotubular myopathy (TRIM32), microtubular abnormalities and 
myosin-containing inclusions (TRIM54 and TRIM63
121
), illustrating the increasingly fluid 
boundaries between the CMs and other neuromuscular disorders, in particular myofibrillar, 
protein aggregation and vacuolar myopathies.   
 
PATHOGENESIS 
 
The vast majority of the proteins implicated in the CMs have been associated with primary or 
secondary defects of muscle excitation-contraction coupling (ECC), intracellular calcium 
homeostasis and disturbed sarcomeric assembly and function (illustrated in Figure 2); other 
mechanisms are currently emerging. 
 
ECC, muscle contraction and relaxation  
 
Excitation-contraction coupling (ECC) is the process whereby an electrical signal generated 
by a neuronal action potential is converted into a chemical gradient, i.e. an increase in 
myoplasmic Ca
++
, leading to muscle contraction. The two main players of skeletal muscle 
ECC are the ryanodine receptor sarcoplasmic reticulum (SR) Ca
++
 release channel (RyR1) 
15 
 
and the voltage sensing L-type Ca
2+
 channel dihydropyridine receptor (DHPR) (Figure 2). 
RyR1 is located on the SR junctional face membrane and the DHPR is located on the 
plasmalemma and transverse tubules, a plasmalemmal invagination running deep into the 
muscle fibre. ECC is extremely rapid, occurring within a few milliseconds, and relies on a 
highly defined subcellular architecture, with each DHPR positioned opposite a RyR1, and 
with every other RyR1 tetramer facing four DHPRs arranged in a characteristic checkerboard 
shape called a tetrad.  
Apart from their principal regulation through direct interaction with DHPR, RyR1s are also 
regulated by Ca
++
 and Mg
++
, and are additionally subjected to post-translational 
modifications (e.g. phosphorylation, sumoylation and nitrosylation) that affect the channel 
open probability. The junctional SR membrane contains the RyR1 as well as many other 
smaller proteins, including the structural proteins triadin and junctin, JP-45, the high 
capacity, low affinity Ca
++
 binding protein calsequestrin 
122,123
 in an area adjacent to RyR1, 
and others that play a role in the fine regulation of SR Ca
++
 release or in maintaining the 
structural integrity of the Ca
++
 release machinery 
122,124-131
.  
Following Ca
++
 release from the SR, its binding to Troponin C, and direct thin-filament 
interaction, muscle contraction occurs in the sarcomere, a structure principally composed of 
parallel thick and thin filaments. Sarcomeric regulation of contraction involves structural 
changes in the thin filament complex composed of actin, tropomyosin and troponin, triggered 
by Ca
++
 binding to troponin. The simplest model for sarcomeric Ca
++
 regulation is based on 
steric-blocking, where tropomyosin prevents myosin binding to the actin filament to generate 
force. Ca
++
 binding to troponin triggers a chain of reactions that result in azimuthal 
movements of tropomyosin around the filament to unmask binding sites on actin for myosin, 
the molecular motor and also major component of the thick filament, allowing force 
16 
 
production and motion 
132
 All these contractile proteins and related isoforms are differently 
expressed in slow and fast twitch muscles to fulfil different functional demands 
132
.  
Termination of the contraction cycle and muscle relaxation is then achieved by RyR1 
closure and by activation of the sarco/endoplasmic reticulum Ca
++
 ATPase (SERCA), the 
protein component responsible for pumping the Ca
++ 
back into the SR 
133
. SERCA activity 
can be modulated by two small regulatory proteins, sarcolipin and phospholamaban 
134-136
.  
Although skeletal muscle ECC can occur in the presence of extracellular Ca
++
 in the nM 
range, there is a wide consensus that Ca
++
 entry from the extracellular space is essential to 
ensure prolonged muscle activity. Two main mechanisms of Ca
++
 entry have been identified 
in skeletal muscle, (i) excitation-coupled Ca
++
 entry (ECCE) via DHPR which is activated by 
a train of action potentials or prolonged membrane depolarisation, and (ii) store-operated 
Ca
++
 entry (SOCE) via STIM1 and Ora1 which is triggered by ER/SR store depletion 
137-141
.  
 
ECC and Ca
++
 homeostasis abnormalities 
 
Amongst the primary defects of ECC and Ca
++
 homeostasis, mutations in RYR1 are the most 
common cause 
7,18,142,143
: Based on functional studies utilizing cellular and animal models [for 
review 
144
] 
145
, excessive Ca
++
 release and lower RyR1 activation thresholds are consequences of 
dominantly inherited MHS-associated RYR1 mutations, whereas both SR calcium store depletion 
with resulting increased cytosolic calcium levels (“leaky channel” hypothesis) and disturbed EC 
coupling (“EC uncoupling hypothesis”) have been proposed for dominantly inherited CCD 142. 
Based on limited studies performed so far, quantitative reduction of RyR1 channels is a more 
likely mechanism than a qualitative RyR1 dysfunction in recessive RYR1-related myopathies 
146-
148
.  (Secondary or primary) reduction of the Cav1.1 protein is seen in both recessive RYR1- and 
CACNA1S-related CMs 
95,146
, the latter also showing disturbed ECC and, consequently, reduced 
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depolarization-induced SR Ca
++
 release in myotubes and mature muscle fibres. STAC3, the gene 
homozygously mutated in NAM, targets Cav1.1 to the T-tubules and thus also participates in 
voltage-induced Ca
++
 release 
149,150
. A similar mechanism is likely to be involved in the recently 
described “triadin knockout syndrome” 119, although the basis for the highly variable penetrance 
of skeletal muscle features in this condition is currently uncertain. Distinct alterations in store 
operated Ca
++
 influx have been described with dominant mutations in STIM1 and ORAI1, 
resulting in increased resting Ca
++
 levels due to constitutively active molecules mediating Ca
++
 
influx independently of SR Ca
++
 levels 
140,151
; the opposite effect, impaired Ca
++
 influx, is seen 
with recessive ORAI1 mutations leading to reduced Orai1 expression 
152
.  
Secondary defects of ECC and Ca
++
 homeostasis have been demonstrated in SEPN1-mutated 
myotubes and in the SEPN1 KO mouse model 
153,154
, probably due to RyR1 redox modifications. 
Many of the genes implicated in CNM – MTM1 40, DNM2 41, and BIN1 44 – code for proteins that 
have an important role in intricately linked intracellular membrane trafficking pathways and may 
thus indirectly affect muscle Ca
++
 handling and ECC, probably secondary to abnormalities of triad 
assembly and the ECC machinery (for review, 
155
). Although such abnormalities have been 
demonstrated in mouse models of both DNM2- and MTM1-related myopathies 
156
, a recent study 
on MTM1-mutated human myoblasts failed to demonstrate any alterations in ECC and Ca
++
 
release, indicating that those alterations may reflect long-term effects in vivo 
157
. Lastly, 
pathogenicity of TTN mutations, although probably multifactorial, is also likely to include several 
mechanisms implicated in ECC, including calpain-3 mediated RyR1 recruitment to the triad, and 
obscurin-mediated interactions between the T-tubules, SR and the sarcomere.  
 
Abnormalities of sarcomeric assembly and function 
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The majority of the genes implicated in NM to date – NEB 59, ACTA1 61, TPM2 158, TPM3 62 
and TNNT1 
68
 – are involved in thin filament assembly and interactions. Pathogenic 
mutations in the two most commonly mutated genes, NEB and ACTA1, have been extensively 
studied [reviewed in 
159
]: Mediated through lowered Ca
++
 sensitivity, dominant ACTA1 
mutations exert a dominant negative effect on muscle function, whereas recessive ACTA1 
mutations abolish functional protein expression, with phenotype severity probably reliant on 
the expression of compensatory proteins such as ACTC 
160,161
. Rarely, ACTA1 may result in 
enhanced muscle contractility
162,163
. NEB mutations affect the specific role of nebulin in thin 
filament regulation and force generation 
164
. The specific effects of various NM-associated 
mutations on nebulin interactions with actin and tropomyosin 
165
, thin filament length and 
force generation 
166
 has been demonstrated in two recent studies in vitro. MYO18B recently 
found to be mutated in one family with a severe form of NM
75
 encodes an unconventional 
myosin with a more general role in sarcomeric assembly and maintenance
167,168
.    
Many of the genes more recently implicated in NM - KBTD13, KLHL40, KLHL41 and 
LMOD3 – encode a group of Kelch- and associated proteins that are not primary thin filament 
components but that are involved in muscle quality control processes 
169
 and may thus affect 
myofibrillar assembly and function indirectly. Evidence for a direct interaction between 
KLHL40, nebulin and leiomodin 3, respectively, has been recently provided 
170
. The 
myosinopathies 
99
, disorders of the thick filament, are likely to cause muscle disease by two 
principal mechanisms, disturbed thick filament interaction and function, and, in particular in 
MYH7-related CMs 
99
, aggregation of abnormal protein.    
 
Other pathogenic mechanisms implicated in the CMs 
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Whilst some of the proteins implicated in the CMs are very specifically involved in ECC and 
calcium homeostasis, others have (putative) additional roles in and beyond muscle. 
Selenoprotein N encoded by SEPN1 is a member of a protein family mediating the various 
biological effects of selenium and in muscle has been specifically implicated in myogenesis, 
a role shared with MEGF10 mutated in a rarer form of MmD
23
,  and redox regulation 
171,172
. 
The important role of normally functioning redox regulation for muscle health is also 
illustrated by the recent identification of recessive mutations in the oxireductase PYROXD1 
as a cause of early-onset congenital myopathies 
98
. Reflective of their essential roles in 
intricately linked intracellular membrane trafficking pathways, mutations in the CNM-
associated genes MTM1, DNM2 and BIN1 have been associated with a wide range of 
downstream effects, including defects in mitochondria, the desmin cytoskeleton, satellite cell 
activation and the neuromuscular junction (for review, 
155
). Abnormalities of muscle 
membrane systems have also been described in association with canine HACD1/PTPLA-
related CNM
86,87
, a naturally occurring animal model of a non-specific congenital myopathy 
recently described in humans
173
. The CNM-associated genes MTM1 and DNM2 have now 
also been implicated in pathways that may affect muscle protein turnover and/or muscle 
growth and atrophy pathways: Disturbances of the autophagy pathway have been reported in 
zebrafish and mouse models of myotubularin deficiency, associated with atrogin upregulation 
and atrophy 
174-176
. Abnormalities of autophagosome maturation and autophagic flux have 
also been described in a mouse model of DNM2-related CNM, associated with marked 
muscle atrophy and weakness 
177
. Autophagy and other degradation pathways may be also be 
affected in TTN-related CNM, through abrogation of calpain-3 mediated protein turnover 
with C-terminal truncating TTN mutations or its links with the ubiquitin ligase myospryn 
178
, 
or through disruption of the link between the kinase domain and the autophagy cargo 
adaptors Nbr1 and SQSTM1 by M-band disrupting TTN mutations 
25
. Intriguingly, the typical 
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histopathological appearance of CNM has now also been reported in primary disorders of 
autophagy
179,180
, further supporting a close link between defective autophagy and abnormal 
nuclear positioning. A novel epigenetic mechanism involving alterations of muscle specific 
microRNAs, increased DNA methylation and increased expression of class II histone 
deacetylases has been recently reported in RYR1-related myopathies 
181
 but may also be 
relevant for other congenital myopathies 
157
. How mutations in ECEL1, PIEZO2 and SCN4A 
cause specific early-onset CMs is currently uncertain. 
 
DIAGNOSTIC APPROACH 
 
A structured diagnostic approach to the CMs is summarized in 
182
. Whilst many features on 
clinical assessment – weakness and hypotonia pronounced axially – are consistent but non-
specific, others, in particular the degree of distal, extraocular muscle, cardiac and respiratory 
involvement, may indicate specific genetic backgrounds. Useful laboratory investigations 
include serum CK levels, typically normal or slightly elevated, and acetylcholine receptor 
(AChR) antibodies, to exclude autoimmune myasthenic conditions 
183
. Neurophysiological 
studies including electromyography (EMG) and nerve conduction studies (NCS) are mainly 
useful for excluding congenital neuropathies, myotonic disorders 111 or congenital myasthenic 
syndromes 184. Muscle imaging (for review 6),  in particular muscle ultrasound (US) as a 
screening test and muscle magnetic resonance imaging (MRI) for a more detailed assessment, 
may reveal diagnostic patterns of selective muscle involvement. Muscle biopsy assessment 
with a standard panel of histological, histochemical and immunohistochemical stains (for 
review, 
13
) will confirm the specific CM, and exclude distinct conditions with overlapping 
pathological features such as the congenital muscular dystrophies (CMDs) 
185
, myofibrillar 
myopathies (MFMs) 
186
 and autophagic vacuolar myopathies (AVMs) 
187
. Electron 
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microscopy (EM) is very helpful to clarify the pathognomic structural abnormalities seen 
with light microscopy. Concomitant analysis of multiple CM-associated genes through NGS 
is rapidly becoming the preferred diagnostic approach. Functional studies will become 
increasingly relevant for pathogenicity assessment of variants in large genes such as TTN, 
NEB and RYR1, in which genetic variants of uncertain significance are not uncommon even 
in healthy control populations.  
 
MANAGEMENT AND THERAPY DEVELOPMENT 
 
Supportive management (outlined in detail in 
188
) is based on a multidisciplinary approach: 
Regular physiotherapy and provision of orthotic support is beneficial to prevent contracture 
development and to maintain mobility. Dysarthria and feeding difficulties will benefit from 
regular speech language therapy input; in some cases bulbar involvement and poor weight 
gain may require gastrostomy insertion. Regular respiratory function monitoring (including 
sleep studies) and proactive respiratory management (including timely non-invasive 
ventilation and cough assistance techniques) are mandatory particularly in forms where 
substantial respiratory involvement, often out of proportion to the degree of limb girdle 
weakness, is recognized. Regular cardiac monitoring is crucial in CMs with consistently 
associated cardiomyopathies (in particular TTN- and MYH7- related forms), but also in 
individuals where the genetic defect is uncertain. Considering often complex comorbidities, 
orthopaedic (in particular scoliosis) surgery should be undertaken at a tertiary neuromuscular 
centre. MHS has to be anticipated in the anaesthetic management of RYR1- and STAC3-
mutated patients and those with unresolved genetic backgrounds.  
Already available or currently developed therapies for the CMs detailed below are reviewed 
in 
189
.  
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Genetic therapies: Due to their enormous size, viral-based gene transfer is unsuitable for 
most genes commonly implicated in the CMs. However, delivery of MTM1 through an 
AAV8-based vector has been demonstrated to improve the clinico-pathological phenotype in 
Mtm1-deficient mice and a canine model of XLMTM 
173,190
. Restoring the mRNA reading 
frame is in theory applicable to various CMs where nonsense mutations are implicated. Exon 
skipping has been successfully applied in vitro to remove the incorporation of a pseudo-exon 
in the mRNA of a child with a recessive RYR1-related myopathy 
191
. Considering that carriers 
of truncating RYR1 mutations are asymptomatic 
191,192
, mutant gene selective silencing may 
also become feasible therapeutic strategy for dominant RYR1-related myopathies in future. 
Pharmacological suppression of stop codons 
193
 with compounds such as PTC124 (Ataluren) 
is a potential approach in CMs where nonsense mutations are involved, although it is 
currently uncertain if such an approach will increase normal protein levels sufficiently to 
restore structural integrity and function, and what the effects on the many loss-of-function 
variants in the human genome 
194
 will be. Down- or upregulation of genes acting in related 
pathways may become particular relevant for different forms of CNM: Recent studies 
demonstrate that dynamin 2 downregulation 
195
, or targeting of class II and III PI3 kinases in 
muscle 
196
 can rescue the phenotype in XLMTM animal models, suggesting pharmacological 
modification of intricately linked pathways a potential treatment modality for XLMTM and, 
possibly, other forms of CNM. Upregulation of cardiac actin may be a therapeutic approach 
for patients with ACTA1 null mutations 
197,198
.  
Enzyme replacement therapy is currently only relevant to XLMTM due to loss of 
myotubularin function, where in Mtm1 KO mice improvements of contractile function and 
histopathological features have been observed following short term myotubularin enzyme 
replacement 
199
.  
Pharmacological therapies potentially applicable to the CMs can be grossly divided into 3 
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principal approaches: i) direct modification of altered protein function (for example 
modification of RyR1 release in RYR1-related myopathies) or ii) enhancement of thin-thick 
filament interactions (for example, in some NMs), and iii) those aimed at non-specifically 
ameliorating downstream effects of the specific gene mutation. Modification of RyR1 Ca
++
 
release through the specific RyR1 antagonist Dantrolene 
200
 is the established emergency 
treatment for MH but has also been effectively used in few patients with RYR1-related ERM 
35,201
 and CCD 
202,203
. Other compounds with the potential to treat excessive SR Ca
++
 release 
and/or increased SR Ca
++
 leak are the calstabin-stabilizing 1,4-benzothiazepine derivatives 
JTV519 and S107 (“Rycals”) (for review, 204,205) and the AMPK activator AICAR (or 5-
aminoimidazole-4-carboximide ribonucleoside) 
206,207
, however, safety profiles of these 
compounds in humans and their roles in RYR1-related myopathies associated with reduced 
rather than enhanced calcium conductance are currently uncertain. Enhancement of filament 
interactions and promotion of force production 
208,209
 (either by slowing the rate of calcium 
release from troponin C or directly targeting myosin molecules) are potentially valuable for 
some NMs, however, concerns remain concerning fibre type specificity and/or potential 
cardiac side-effects of the molecules utilized. Modification of downstream effect of specific 
gene mutations comprises various approaches: Inhibition of myostatin, an important negative 
regulator of muscle fibre size 
210
, may be applicable to CMs where fibre atrophy is 
prominent. Based on the observation of increased oxidative stress and a favourable response 
to these compounds in animal models 
154,211,212
, antioxidants such as N-acetylcysteine (NAC) 
are currently being investigated in clinical trials concerning RYR1- and SEPN1-related 
myopathies. Based on neuromuscular junction/transmission abnormalities in CNM, RYR1-
related MmD and KLHL40-related NM 
213-216
, acetylcholinesterase inhibitors have been used 
with some benefit in a small number of patients. Two other compounds where an apparent 
benefit was demonstrated in two small open label pilot studies are salbutamol in core 
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myopathies 
217-219
 and, also supported by pre-clinical data from a relevant animal model 
220
, 
L-Tyrosine in NM 
221
. For those disease entities where misfolded proteins or domains play 
unequivocal primary roles in the disease process (e.g. titin in AR MmD-HD), the 
development of compounds acting as “chemical chaperones” might bear promise: A 
pharmacochaperone approach, using the small amphipathic compound 4-phenylbutyrate, was 
recently shown to alleviate some of the pathological features in a mouse model of PLEC-
associated epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) 
222
, although it 
is uncertain if the observed effect was due to stabilisation of misfolded mutant protein, or its 
clearance through autophagy induction by the “pleiotropic” drug 4-phenylbutyrate (4PBA) 
223,224
. A beneficial effect of 4PBA has recently also been suggested in a mouse model of a 
RYR1-related myopathy 
225
. The range of chemical chaperones is increasing rapidly 
226
, but 
their effective concentrations (IC50) are often still very low 
227
, and the development of more 
target-specific compounds might make this approach more effective and applicable.  
  
CONCLUSIONS AND OUTLOOK 
 
Widespread clinical implementation of NGS has rapidly expanded the genetic and clinico-
pathological spectrum of the CMs, which – in addition to the “classical” entities CCD, MmD, 
CNM and NM – now encompass a wide range of early-onset non-dystrophic neuromuscular 
disorders with variable combinations of structural defects. CMs due to mutations in RYR1, 
the most common genetic cause, show a continuum with intermittent induced myopathies – 
MH and (exertional) rhabdomyolysis – in otherwise healthy individuals, whilst there is 
substantial overlap with the distal arthrogryposis and protein aggregation myopathy spectrum 
particularly in forms where sarcomeric proteins are implicated. Unravelling the underlying 
molecular mechanisms has not only advanced the understanding of the CMs but also our 
25 
 
knowledge of normal muscle physiology and homeostasis: Whilst the primary genetic defects 
and principal pathogenic mechanisms have been largely elucidated, downstream effects on 
muscle growth and atrophy pathways, the role of (genetic) modifiers and the molecular basis 
for the common histopathological features remain largely uncertain.  Specific therapies 
utilizing multiple – including genetic, enzyme replacement and pharmacological - approaches 
are currently being developed, or are already reaching the clinical trial stage, emphasizing the 
need for comprehensive natural history studies concerning these clinically variable 
conditions. 
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FIGURE AND TABLE LEGENDS 
 
FIGURES 
 
Figure 1  
Muscle pathology in congenital myopathies, illustrating the key pathological features of the 
congenital myopathies, central cores, multiple minicores, central nuclei and nemaline rods. 
RYR1–related Central Core Disease (CCD) (a-c), SEPN1–related Multi-minicore Disease 
(MmD) (d-f), Centronuclear Myopathy (CNM) (g-i MTM1- and j-l DNM2-related), and 
ACTA1–related Nemaline Myopathy (NM) (m-o). Muscle biopsies stained with haematoxylin 
and eosin (H&E) (a,d,g,j,m), NADH-TR (b,e,h,k), modified Gomori Trichrome (n), slow 
myosin heavy chain (c,f,i,l), and myosin ATPase pH 4.6 (o). a) Child with dominant RYR1-
related CCD shows myopathic fibre size variation and marked perimysial fatty infiltration. b) 
Most fibres contain a single central or eccentric ‘core’ with a well-delineated zone of 
diminished or absent oxidative staining; some of these also show a rim of enhanced oxidative 
staining surrounding the core lesion. c) There is uniformity of type I/slow fibres. d) 
Adolescent with recessive SEPN1-related MmD shows myopathic fibre size variation and 
perimysial fatty infiltration. e,f) Fibre typing is preserved with predominance of type 1/slow 
fibres, and both type I and type II fibres display foci areas of diminished or absent oxidative 
staining (multi-minicores) and occasionally larger lesions. g) Male neonate with severe X-
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linked recessive myotubular myopathy (XLMTM) shows centrally placed nuclei in a large 
number of fibres. h) The majority of fibres display pale peripheral halos and (i) type I/slow 
fibres are predominant. j) Adult with DNM2-related CNM shows marked increase in central 
nucleation and perimysial fatty infiltration. k) Many fibres display ‘radial strands’ radiating 
from a centrally placed nucleus. l) There is type I/slow fibre predominance and hypotrophy 
creating fibre size disproportion; central nuclei are present in both fibre types. m) Severely 
affected neonate with de novo dominant ACTA1-related NM shows myopathic fibre size 
variation with an appearance of two fibre populations mostly of smaller type I and larger type 
II fibres (see o). n) Numerous thread-like inclusions are seen in both fibre sizes and appear 
red with the modified Gomori trichrome and eosinophilic with haematoxylin and eosin (m). 
o) Pale stained type I fibres are often more severely affected and atrophic/hypotrophic. Scale 
bar: (a-f, i-m, o = 100 µm; g,h,n = 10 µm) 
 
Figure 2  
Subcellular localization of the main proteins implicated in skeletal muscle excitation-
contraction coupling (ECC), thin-thick filament interaction and assembly. Mutations in 
genes encoding components of the ECC machinery and thin-thick filaments of skeletal 
muscle are commonly mutated in the congenital myopathies. The transverse tubules are 
invaginations of the plasma membrane where the DHPR complex (containing STAC3) is 
located. This membrane compartment faces the sarcoplasmic reticulum (SR) junctional face 
membrane (JFM), containing the ryanodine receptor calcium release channel (RyR1) as well 
as JP-45 and the strucutural proteins triadin and junctin. Calsequestrin bound to calcium 
forms a mesh-like structure within the lumen of the SR terminal cisternae. JP-45 also 
interacts with calsequestrin via its lumenal carboxy-terminal domain. Calcium release into 
the cytosol results in sarcomeric shortening through specific interactions between thin-thick 
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filaments, in particular sliding of actin past myosin filaments. The ECC is terminated through 
SR calcium re-uptake through SERCA calcium pumps. SERCAs are present in the terminal 
cisternae as well as the longitudinal SR, and are regulated by phospholamban, myoregulin 
and sarcolipin. The calcium-bufferring protein sarcalumenin is also located in the 
longitudinal sarcoplasmic reticulum and terminal cisternae and is also involved in regulating 
SERCA activity. (Objects not to scale). Image kindly provided by Christoph Bachmann, 
Departments of Anesthesia and Biomedicine, Basel University Hospital, Basel, Switzerland. 
 
TABLES 
 
Table 1  
Genes implicated in the congenital myopathies and related conditions. Genes that are 
most commonly implicated in the “classical” structural congenital myopathies (and their most 
commonly associated histopathological features) are highlighted in bold. AD = autosomal-
dominant; AR = autosomal-recessive; CM = Congenital myopathy (non-specific); CCD = 
Central Core Disease; MmD = Multi-minicore Disease; CNM = Centronuclear Myopathy 
(CNM); XLMTM = X-linked myotubular myopathy; NM = Nemaline Myopathy; CFTD = 
Congenital Fibre Type Disproportion; KDS = King-Denborough syndrome (KDS); NAM = 
North American Myopathy (NAM); TAM = Tubular Aggregate Myopathy (TAM); MSM = 
Myosin Storage Myopathy; DA = Distal Arthrogryposis; EOM = extraocular muscle 
involvement; CN = central nuclei;  
 
Table 2  
Genetic, clinical and pathological features associated with different genetic 
backgrounds commonly implicated in the congenital myopathies.  RYR1 = skeletal 
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muscle ryanodine receptor gene; SEPN1 = selenoprotein N gene; TTN = titin gene;   MTM1 = 
myotubularin gene, DNM2 = dynamin gene, NEB = Nebulin gene, ACTA1 = skeletal muscle 
α-actin gene; KLHL40 = kelch-like family member 40.  - = not reported, + = infrequent, ++ = 
common and +++ = very common. a = right ventricular impairment secondary to respiratory 
involvement. b = includes both congential cardiac defects and acquired cardiomyopathies.  
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Table 1 
Gene 
symb
ol 
Chromo
some 
location 
Protein Condition 
Inherit
ance 
Proteins involved in SR calcium release, ECC and/or triadic assembly 
RYR1 19q13.1 Ryanodine receptor 1 (skeletal) 
CCD 
MmD  
CNM  
CFTD 
KDS 
AD, AR 
AD, AR 
AR 
AR 
AR, AD 
STAC
3 
12q13.3 SH3 and Cystein-rich domain 3 NAM AR 
ORAI1 
12q24.3
1  
Calcium release-activated calcium 
modulator 1 
TAM AD 
STIM1 11p15.4 Stromal interactin molecular 1 
TAM 
Stormorken syndrome  
AD 
AD 
MTM1 Xq28 Myotubularin XLMTM 
X-
linked 
BIN1 2q14 Amphiphysin CNM AR, AD 
DNM2 19p13.2 Dynamin 2 CNM AD 
SPEG 2q35 SPEG complex locus CM with CN and cardiomyopathy AR 
CCDC
78 
16p13.3 
Coiled-coil domain containing 
protein 78 
CM with cores and CN AD 
CACN
A1S 
1q32 
Calcium channel, voltage-
dependent, L type, alpha 1S 
subunit 
CM with EOM AD, AR 
SEPN
1 
1p36.13 Selenoprotein N1 
MmD 
CFTD 
AR 
AR 
Proteins involved in thick-thin filament assembly and interaction, myofibrillar force generation 
and protein turnover 
NEB 2q22 Nebulin NM AR 
ACTA
1 
1q42.1 Alpha actin, skeletal muscle  
NM 
CFTD 
Cap myopathy 
AD, AR  
AD, AR 
AD, AR  
AD, AR 
TNNT
1 
19q13.4 Slow troponin T NM AR 
TPM2 9p13 Tropomyosin 2 (beta) 
NM 
Cap myopathy 
DA1A  
DA2B 
Escobar syndrome  
AD 
AD 
AD 
AD 
AR 
TPM3 1q21.2 Tropomyosin 3 
NM 
CFTD 
Cap myopathy 
AD 
AD 
AD 
MYH2 17p13.1 
Myosin, heavy polypeptide 2, 
skeletal muscle 
CM with EOM 
AD, AR 
 
MYH3 17p13.1 
Myosin, heavy polypeptide 3, 
skeletal muscle, embryonic 
DA 2A, 2B and 8 AD 
MYH7 14q12 
Myosin, heavy polypeptide 7, 
cardiac muscle, beta 
CFTD 
MmD 
MSM 
AD 
AR 
AR 
MYH8 17p13.1 
Myosin, heavy polypeptide 8, 
skeletal muscle, neonatal  
Trismus, pseudocamptodactyly 
syndrome 
Carney complex 
AD 
AD 
KBTB
D13 
15q22.3
1 
Kelch repeat and BTB (POZ) 
domain containing 13 
NM with cores AD 
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KLHL
40 
2p22.1 Kelch-like family member 40 NM AR 
KLHL4
1 
2q31.1 Kelch-like family member 41 NM AR 
LMOD
3 
3p14.1 Leiomodin 3 (fetal) NM AR 
MYBP
C3 
11p11.2 Cardiac myosin binding protein-C CM with cardiomyopathy  AR 
MYPN 10q21.3 Myopalladin NM with cardiomyopathy AR 
TTN 2q31 Titin  
CNM 
MmD 
AR 
AR 
 
Proteins involved in other cellular processes or with unknown functions 
 
CFL2 14q12 Cofilin 2 (muscle) NM with cores AR 
CNTN
1 
12q11-
q12 
Contactin-1 CM lethal AR 
ECEL
1 
 2q37.1  
Endothelin converting enzyme-like 
protein 1 
DA5 AR 
PIEZO
2 
 18p11.2
1-22 
Piezo-Type mechanosensitive ion 
channel component 2 
Marden-Walker syndrome 
DA3  
DA5 
DA with impaired proprioception 
AD 
AD 
AD 
AR 
MEGF
10 
5q23.2 Multiple EGF-like-domains 10 
CM with minicores 
CM with areflexia, respiratory 
distress and dysphagia 
AR 
AR 
 
HACD
1 
10p12.3
3 
Protein tyrosine phosphatase-like 
(3-Hydroxyacyl-CoA dehydratase 
CM AR 
SCN4
A 
17q23.3 
Sodium channel, voltage gated type 
IV, alpha subunit 
CM AR 
TRIM3
2 
9q33.2 Tripartite motif-containing 32 Sarcotubular myopathy AR 
PYRO
XD1 
12p12.1 
Pyridine nucleotide-disulfide 
oxidoreductase domain-containing 
protein  
CM AR 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
 
Gene RYR1 
AD 
RYR1 
AR  
SEPN1   
TTN 
MTM1 DNM2 NEB ACTA1   
KLHL40 
Frequency +++ +++ ++   ++ ++ + ++ ++   + 
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Onset          
-  Infancy ++ +++ +   
+++ 
+++ + +++ ++   +++ 
- Childhood +++ ++ +++   + + + + ++   + 
- Adulthood ++ + -   - - +++ - -   - 
Clinical 
features 
         
- EOM + +++ -   - +++ +++ - -   ++ 
- Bulbar 
involvement 
+ +++ ++   ++ +++ ++ ++ ++   +++ 
- Distal 
involvement 
- + -   ++ + +++ ++ +   + 
- Respiratory 
Involvement 
+ ++ +++   ++ +++ + ++ ++   +++ 
- Cardiac 
Involvement 
- + +a   
+++ 
b 
- - - +    
- Contractures + + +   
+++ 
+++ ++ ++ ++   +++ 
Histopathology          
- Cores +++ +++ +++   ++ - + + +    
- Central nuclei ++ ++ -   
+++ 
+++ +++ - -    
- Nemaline rods 
Muscle MRI 
(specifity)  
+ 
+++ 
+ 
++ 
- 
++ 
  + - 
+ 
- 
+++ 
+++ 
+++ 
+++ 
+ 
  +++ 
- FTD + +++ +   + + - - +  
- Connective 
tissue/Fat 
++ ++ ++   
+++ 
- + - -  
 
